Third Rock launches Maze with $191M to target genetic modifiers

Maze Therapeutics (San Francisco, Calif.) launched Thursday with $191 million to develop treatments targeting genetic modifiers. The company is combining large-scale human genetics and functional genomics to analyze how modifier genes confer protection and how to target those genes with drug therapies.

Third Rock Ventures and Arch Venture Partners led the financing, with participation from GV, Foresite Capital, Casdin Capital, Alexandria Venture Investments and other undisclosed investors. Third Rock's Charles Homcy said the financing will provide the company with 3-5 years of runway (see “Navigating Third Rock’s Maze”)...